X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GLENMARK PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GLENMARK PHARMA ASTRAZENECA PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 90.5 13.6 664.2% View Chart
P/BV x 12.9 3.8 337.7% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
GLENMARK PHARMA
Mar-16
ASTRAZENECA PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2851,262 101.8%   
Low Rs634672 94.4%   
Sales per share (Unadj.) Rs189.6270.6 70.1%  
Earnings per share (Unadj.) Rs-0.224.9 -0.8%  
Cash flow per share (Unadj.) Rs3.834.4 11.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs68.6151.3 45.4%  
Shares outstanding (eoy) m25.00282.16 8.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.6 141.6%   
Avg P/E ratio x-4,712.738.9 -12,126.6%  
P/CF ratio (eoy) x249.628.1 888.5%  
Price / Book Value ratio x14.06.4 218.8%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m23,988272,778 8.8%   
No. of employees `0001.610.0 15.6%   
Total wages/salary Rs m1,60513,782 11.6%   
Avg. sales/employee Rs Th3,040.27,614.9 39.9%   
Avg. wages/employee Rs Th1,029.21,374.8 74.9%   
Avg. net profit/employee Rs Th-3.3700.2 -0.5%   
INCOME DATA
Net Sales Rs m4,74076,340 6.2%  
Other income Rs m92356 25.9%   
Total revenues Rs m4,83276,696 6.3%   
Gross profit Rs m-13014,172 -0.9%  
Depreciation Rs m1012,691 3.8%   
Interest Rs m01,789 0.0%   
Profit before tax Rs m-13910,048 -1.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m53,028 0.2%   
Profit after tax Rs m-57,019 -0.1%  
Gross profit margin %-2.718.6 -14.8%  
Effective tax rate %-3.730.1 -12.2%   
Net profit margin %-0.19.2 -1.2%  
BALANCE SHEET DATA
Current assets Rs m2,72659,096 4.6%   
Current liabilities Rs m2,43540,018 6.1%   
Net working cap to sales %6.125.0 24.6%  
Current ratio x1.11.5 75.8%  
Inventory Days Days7475 98.4%  
Debtors Days Days41119 34.2%  
Net fixed assets Rs m1,03539,075 2.6%   
Share capital Rs m50282 17.7%   
"Free" reserves Rs m94230,281 3.1%   
Net worth Rs m1,71642,703 4.0%   
Long term debt Rs m024,873 0.0%   
Total assets Rs m4,156111,026 3.7%  
Interest coverage xNM6.6-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.10.7 165.9%   
Return on assets %-0.17.9 -1.5%  
Return on equity %-0.316.4 -1.8%  
Return on capital %017.5 0.0%  
Exports to sales %5.743.3 13.2%   
Imports to sales %6.57.4 87.0%   
Exports (fob) Rs m27033,044 0.8%   
Imports (cif) Rs m3065,672 5.4%   
Fx inflow Rs m37536,945 1.0%   
Fx outflow Rs m47061,066 0.8%   
Net fx Rs m-96-24,122 0.4%   
CASH FLOW
From Operations Rs m-83,449 -0.2%  
From Investments Rs m-146-8,802 1.7%  
From Financial Activity Rs m8626,986 12.3%  
Net Cashflow Rs m709934 75.9%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 6.9 4.3%  
FIIs % 15.7 34.4 45.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   12,856 56,727 22.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Energy Stocks Witness Buying(11:30 am)

After opening the day in green, Share markets in India witnessed volatile trading activity and are presently trading marginally above the dotted line.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 22, 2017 12:55 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS